A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.
Aditi R SaxenaStephanie-An LyleKaivan KhavandiRuolun QiuMark WhitlockWilliam P EslerAlbert M KimPublished in: Diabetes, obesity & metabolism (2023)
PF-06835919 administration over 16 weeks was generally safe and well tolerated and resulted in reductions in WLF in participants with NAFLD and T2D.